United States · Health Care · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Anbio Biotechnology? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
| ROE | 14.83% | 13.81% | 14.03% | 12.74% | 11.75% | 11.38% |
|---|---|---|---|---|---|---|
| ROA | 13.66% | 12.57% | 12.82% | 11.68% | 10.8% | 10.47% |
| Gross Margin | 71.9% | 71.76% | 71.16% | 70.81% | 70.08% | 70.18% |
| Net Margin | 28.99% | 28.22% | 30.19% | 28.14% | 27.3% | 27.58% |
| Total Assets | $18,921.78K | $21,644.29K | $24,812.14K | $28,112.66K | $31,564.87K | $35,319.87K |
| Net Income | $2,372.84K | $2,549.48K | $2,977.52K | $3,091.16K | $3,221.91K | $3,501.69K |